In the context of the vigorous development of China's pharmaceutical industry, many multinational pharmaceutical companies have taken the Chinese market as one of
the key layout objects.
It is worth noting that as the reform of China's pharmaceutical market continues to deepen and the environment for innovation and research and development continues to improve, multinational pharmaceutical companies are accelerating the pace of development and beginning to further cultivate the Chinese market
.
Recently, some media revealed that Bayernand China will establish a Shenzhen region in the field of women's health treatment, responsible for the product promotion function
of the Shenzhen market and some markets in eastern Guangdong.
Bayer said that this move is to further implement the TCN strategy of prescription drugs in China, maximize the support for the rapid growth of the women's health treatment field, and based on product line strategy and regional layout considerations
.
It is reported that Luo Jiang, currently the senior regional manager of Guangzhou Group 3 in the field of women's health treatment in South China, will be promoted to the regional manager of Shenzhen Region in the field of women's health treatment in South China, reporting
directly to Xiao Lu, director of the field of women's health treatment in South China.
At present, Shenzhen 1 group, Shenzhen 2 group and Guangzhou 4 groups in the field of women's health treatment in South China will be divided into Shenzhen regional structure, and the corresponding manager will report to Luo Jiang, the regional manager of Shenzhen region.
.
.
The above changes will take effect
on November 1, 2022.
On October 18, ZEISS launched
its first self-construction project in Suzhou.
It is reported that ZEISS laid the foundation stone in Suzhou Industrial Park to start the construction of the "Fengqi" project, which is the first self-built project of ZEISS in China to purchase land, marking the further deepening and expansion
of ZEISS' localization process in China.
The completion of the new project will help ZEISS leverage Suzhou's deep manufacturing, talent and industrial chain advantages, accelerate joint innovation with partners, and build a more resilient and sustainable industrial ecosystem in the Yangtze River Delta region
.
It is worth mentioning that in addition to launching the construction of the "Fengqi" project, the relevant person in charge also said that in the future, ZEISS will continue to increase investment in the Chinese market, further deepen the localization innovation strategy, and help the upgrading of "Made in China" and the high-quality development
of the big health industry.
On August 25, Inmena also announced the official launch of China's first manufacturing base, which will localize the manufacturing of 16 sequencing reagents for clinical application in the first phase, and is scheduled to be delivered
by the end of this year.
In addition, Inmena also plans to gradually realize the full local production
of high-end gene sequencers and consumables in the next five years.
The total investment in the first phase of the project is nearly 50 million yuan, and the company plans to invest more than 450 million yuan in the next five years to build manufacturing capacity
in China.
.
.
.
.
.
.
At present, China has clearly become one of the important pillars of the global business of many multinational pharmaceutical companies, and with the changes in China's pharmaceutical market, multinational pharmaceutical companies are also accelerating their layout
.
On the whole, for multinational pharmaceutical companies, in addition to making changes in business models, such as accelerating the launch of new products and promoting digitalization; It also includes organizational restructuring, accelerated decision-making, and alignment of new product launches across existing teams in different therapeutic areas
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
